| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Throughout the last three months, 4 analysts have evaluated Omega Therapeutics (NASDAQ:OMGA), offering a diverse set of opinions from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 2 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 1 | 0 | 0 | 0 |
| 2M Ago | 0 | 1 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Analysts have set 12-month price targets for Omega Therapeutics, revealing an average target of $10.5, a high estimate of $12.00, and a low estimate of $6.00. This current average reflects an increase of 1.65% from the previous average price target of $10.33.
A clear picture of Omega Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Robert Burns | HC Wainwright & Co. | Maintains | Buy | $12.00 | $12.00 |
| Robert Driscoll | Wedbush | Maintains | Outperform | $12.00 | $12.00 |
| Keay Nakae | Chardan Capital | Lowers | Buy | $6.00 | $7.00 |
| Ryan Deschner | Raymond James | Announces | Outperform | $12.00 | - |
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Omega Therapeutics's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on Omega Therapeutics analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Omega Therapeutics Inc is a development-stage biotechnology company leveraging its proprietary epigenomic programming platform to biologically engineer a new class of programmable epigenetic medicines, known as Omega Epigenomic Controllers. Using epigenomic controllers, Omega is seeking to transform the practice of human medicine through selective and direct control of the human genome to treat and cure disease. It operates in the U.S.
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Over the 3 months period, Omega Therapeutics showcased positive performance, achieving a revenue growth rate of 181.16% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Omega Therapeutics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -764.06%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Omega Therapeutics's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -48.23%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Omega Therapeutics's ROA stands out, surpassing industry averages. With an impressive ROA of -9.27%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a high debt-to-equity ratio of 4.83, Omega Therapeutics faces challenges in effectively managing its debt levels, indicating potential financial strain.
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: OMGA
